On today’s Stop Trading segment on CNBC, Jim Cramer said he was shocked that Revlimid from Celgene (CELG) was hardly noticed and he thinks it’s ready to run here. This down move in Celgene is a mistake. He’s sticking with his Onyx Pharmaceuticals Inc. (ONXX) after they gave positive data at the American Society of Clinical Onclogy ("ASCO") after the company extended the life of liver cancer patients.
Cramer said he’d still buy Wal-Mart (WMT-NYSE) here even after the run from the news Friday and after the upgrades today.
Jon C. Ogg
June 4, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.
Travel Cards Are Getting Too Good To Ignore (sponsored)
Credit card companies are pulling out all the stops, with the issuers are offering insane travel rewards and perks.
We’re talking huge sign-up bonuses, points on every purchase, and benefits like lounge access, travel credits, and free hotel nights. For travelers, these rewards can add up to thousands of dollars in flights, upgrades, and luxury experiences every year.
It’s like getting paid to travel — and it’s available to qualified borrowers who know where to look.
We’ve rounded up some of the best travel credit cards on the market. Click here to see the list. Don’t miss these offers — they won’t be this good forever.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.